Substituted imidazoles as bombesin receptor subtype-3 modulators
US8106070B2 · kind B2 · utility
0Cited by
3References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 16, 2007 |
| Grant date | Jan 31, 2012 |
| Priority date | — |
| Expiry date | Sep 23, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.